about
Bortezomib for the treatment of multiple myelomaBortezomib for the treatment of multiple myelomaMolecular mechanisms in multiple myeloma drug resistanceNeuropathic cancer pain: What we are dealing with? How to manage it?European perspective on multiple myeloma treatment strategies in 2014Systematic comparison of peptidic proteasome inhibitors highlights the α-ketoamide electrophile as an auspicious reversible lead motifA novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistanceNatural products from mangrove actinomycetes.Novel therapeutic targets in myeloma bone disease.MCPIP1 contributes to the toxicity of proteasome inhibitor MG-132 in HeLa cells by the inhibition of NF-κBSelective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses.Inhibitory effect of b-AP15 on the 20S proteasomeOverview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.SCF(JFK) is a bona fide E3 ligase for ING4 and a potent promoter of the angiogenesis and metastasis of breast cancer.Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple MyelomaMarine-derived angiogenesis inhibitors for cancer therapy.Proteasome inhibitor MG-132 induces MCPIP1 expressionRrp15 affects cell cycle, proliferation, and apoptosis in NIH3T3 cells.Bortezomib for the treatment of previously untreated multiple myeloma.Targeting kallikrein-related peptidases in prostate cancer.Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.Ubiquitination in disease pathogenesis and treatment.Cellular effect and efficacy of carfilzomib depends on cellular net concentration gradient.Acylboranes: synthetic strategies and applications.Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.Computational identification of potential multi-drug combinations for reduction of microglial inflammation in Alzheimer disease.Therapeutic potential of carfilzomib, an irreversible proteasome inhibitor, against acetaminophen-induced hepatotoxicity in mice.CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors.Preclinical comparison of proteasome and ubiquitin E1 enzyme inhibitors in cutaneous squamous cell carcinoma: the identification of mechanisms of differential sensitivity.Ubiquitin Receptor RPN13 Mediates the Inhibitory Interaction of Diphenyldihaloketones CLEFMA and EF24 With the 26S ProteasomeProptosis and hemiplegia as an initial manifestation of multiple myeloma
P2860
Q24185881-7CF0D296-6B66-4098-861B-1A35990D7314Q24202774-E32A5C52-8DDC-4842-A9C1-9B700732413DQ26776386-23B107D7-0C2B-46ED-9512-BFD4DF0B566DQ26998945-9D492A27-B442-4848-B91A-95E337297A4EQ27005966-93A06ECB-6064-4E74-A2BA-5AA0BC20A53CQ27688108-27454BAD-818E-45F6-BDFB-14B68E7CB802Q28395203-E25D2357-C7F8-47BD-A172-F786D1555535Q33736692-3A1B0E28-15C6-4AA4-9648-E5E325643048Q34025065-59C21897-F94D-47E5-ACDB-2357B26C8FA1Q34038263-2505E1FA-7FA3-4BC4-8C49-C472F88AF7A2Q34075096-4951BF82-3804-480F-9245-D6CAB4D11BC8Q34722352-725DB439-75C5-455A-B4EC-CD9D7A24BAABQ34785773-FAB62868-DC32-4F07-9B0F-6B19A3D56216Q34788381-64830DEE-674E-4722-A6E5-2E70895BC5EBQ35005510-67D519E3-750E-479F-8F47-55C6E226A51DQ35228761-0293B390-3F96-4801-9776-E925BB94AF5BQ35832168-3FDB675F-6DC4-4E6E-A830-D347FD031FDDQ36444233-2BE91C48-4043-43C4-BF36-0AD6B8335E64Q36994177-C031898D-F80A-40FD-8A29-C6CB085D756FQ37250219-5444211C-7BA2-4E46-8EC1-7137D354EAEEQ37393115-F27B398E-1FF6-4F7D-A2C4-4D3283EEEC41Q38096055-73505C8A-F8EA-40AF-9518-53143E9910F9Q38191293-B1F927C4-8993-4845-8F45-5703AE8345E1Q38218209-939B469E-7316-4BD0-9262-ED7C2E206CC9Q38265657-6CA8FDFE-1C50-4F39-B5D6-4D6584601F61Q38703639-6283DA90-CE79-4D92-8E58-5D4409EFC60DQ39026981-21D2A4F0-1746-400F-9FE4-EB3D7E270125Q39234159-4D055FAB-2556-4A9E-B396-00952F7E627CQ40813292-50157979-D0BB-496E-9FC7-D7667CE33080Q46452914-674EDF19-04A9-4818-BFED-9A6B7B762B44Q48188365-9CA3F139-3EE2-4C97-A5EF-1720283C311FQ48943059-D9C0E615-1BA1-46A6-B916-9C4076A0A649Q55476988-E37AD56D-DE21-4C0F-ABF0-08820BA75991Q57114402-80DD65D2-E22C-40C7-9308-0C54FB6B5E68Q58791050-C2ABFA35-B5DF-4DBB-B6D4-8E88B17D2D79
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
New proteasome inhibitors in myeloma.
@en
type
label
New proteasome inhibitors in myeloma.
@en
prefLabel
New proteasome inhibitors in myeloma.
@en
P2093
P2860
P1476
New proteasome inhibitors in myeloma.
@en
P2093
Catriona Hayes
Claire Fabre
Constantine Mitsiades
Dharminder Chauhan
Jacob Laubach
Michelle Maglio
Panisinee Lawasut
Teru Hideshima
P2860
P2888
P304
P356
10.1007/S11899-012-0141-2
P577
2012-12-01T00:00:00Z
P5875
P6179
1017617920